Literature DB >> 15663679

Telomerase activity is correlated with lower grade and lower stage bladder carcinomas.

Akiou Okumura1, Ichiro Mizuno, Osamu Nagakawa, Hideki Fuse.   

Abstract

BACKGROUND: Telomerase is a ribonucleoprotein enzyme that compensates for the progressive erosion of telomeres. The increasing interest in telomerase is motivated by the demonstration that most human carcinomas are telomerase positive. The potential use of telomerase activity in bladder carcinomas using a urine sample has been reported in several studies. However, little is known about the detection of telomerase activity in bladder carcinoma tissues. Herein, we investigate telomerase activity in bladder carcinoma tissues according to grade (G) and stage.
MATERIAL AND METHODS: Telomerase activity was assayed by polymerase chain reaction enzyme-linked immunosorbent assay methods. Malignant lesions were assessed in 37 patients with bladder carcinoma and no malignant lesions were assessed in five patients with dysplasia or inflammatory bladder lesions.
RESULTS: Twenty-three out of 37 carcinoma samples were telomerase-positive and one out of five control samples without carcinoma was telomerase-positive. The positive rates according to stage and grade were 83.3% for superficial and 42.1% for invasive stages and 83.3% for G1, 66.7% for G2 and 40.0% for G3. Telomerase activity was correlated with lower grade and lower stage bladder carcinomas.
CONCLUSION: These results strongly suggest that reactivation of telomerase may differ between superficial and invasive bladder carcinomas and also between low grade and high grade bladder carcinomas.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15663679     DOI: 10.1111/j.1442-2042.2004.00960.x

Source DB:  PubMed          Journal:  Int J Urol        ISSN: 0919-8172            Impact factor:   3.369


  6 in total

Review 1.  Telomerase promoter mutations in cancer: an emerging molecular biomarker?

Authors:  João Vinagre; Vasco Pinto; Ricardo Celestino; Marta Reis; Helena Pópulo; Paula Boaventura; Miguel Melo; Telmo Catarino; Jorge Lima; José Manuel Lopes; Valdemar Máximo; Manuel Sobrinho-Simões; Paula Soares
Journal:  Virchows Arch       Date:  2014-07-22       Impact factor: 4.064

2.  Prediction and diagnosis of bladder cancer recurrence based on urinary content of hTERT, SENP1, PPP1CA, and MCM5 transcripts.

Authors:  Anne Sofie Brems-Eskildsen; Karsten Zieger; Helle Toldbod; Cherie Holcomb; Russell Higuchi; Francisco Mansilla; Pia P Munksgaard; Michael Borre; Torben F Ørntoft; Lars Dyrskjøt
Journal:  BMC Cancer       Date:  2010-11-24       Impact factor: 4.430

3.  Telomerase activity in bladder cancer tissue.

Authors:  Akihiro Morii; Akira Komiya; Akiou Okumura; Hideki Fuse
Journal:  Exp Ther Med       Date:  2010-01-01       Impact factor: 2.447

4.  Diagnostic Value of Telomerase Activity in Patients With Bladder Cancer: A Meta-Analysis of Diagnostic Test.

Authors:  Lei Peng; Jinze Li; Chunyang Meng; Jinming Li; Dandan Tang; Fangxue Guan; Peng Xu; Tangqiang Wei; Yunxiang Li
Journal:  Front Oncol       Date:  2020-12-03       Impact factor: 6.244

5.  Urine telomerase for diagnosis and surveillance of bladder cancer.

Authors:  Angela Lamarca; Jorge Barriuso
Journal:  Adv Urol       Date:  2012-07-25

6.  Telomere instability in papillary bladder urothelial carcinomas: Comparison with grading and risk of recurrence.

Authors:  Giuseppe Mucciardi; Alessandro Gali'; Valeria Barresi; Massimo Mucciardi; M'Hammemd Aguennouz; Antonino Inferrera; Carlo Magno
Journal:  Indian J Urol       Date:  2014-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.